Kelton says it`s especially important to target people in a company integrity agreement, “in situations where there are no people who have been criminally convicted.” Such provisions may “become more typical in all comparison agreements,” she says. Two summers ago, GlaxoSmithKline (GSK) made a lot of noise about the fact that it eliminated sales-based compensation and bonuses for U.S. salespeople. Instead of rewarding the biggest sellers, a commercial bonus from 2011 would be determined in part by “customer opinion and respect for the company`s values transparency, integrity, respect and patient orientation.” “,” states a press release of July 26, 2010. Big Pharma talks a lot about the changing business model and puts a new emphasis on patients, but the fact remains that the amount of drugs sold, not the quality of care, is the way to get paid (and keep investors happy). Despite its egalitarian pitfalls, the health “ecosystem” is still dominated by the most skilled hunters, those who catch the most prey. However, new provisions included in the business integrity agreements between the government and Pharma – GSK is the youngest victim – could force companies to change their model or pay the price. The provision significantly increases the individual responsibility of the company and management. If executives feel they are under the microscope and may be subject to monetary sanctions, they will ensure that their direct reporting is much more focused on the compliance requirements outlined in the company integrity agreement. That means they now have “skin in the game” in a way they didn`t have yet, Beimers says. communications to health care providers and paying organizations. As a general rule, pharmaceutical companies that are part of an agreement on the integrity of the company must inform physicians in writing of the comparison.
This agreement goes even further by requiring GSK to send letters to the government and other payers with whom the company has discount agreements and inform them of the comparison. Colgan adds that in recent years, GSK has also “significantly strengthened the compliance program and staff training.” The company now has eight compliance assistants and 79 “integrity champions.” “We are firmly committed to doing everything in our power to meet and exceed the expectations of those with whom we work and serve. Since I bed CEO, we have a clear priority to anchor a culture that puts patients first, that acts transparently, respects people inside and outside the organization and demonstrates integrity in everything we do.